Dune Medical Devices said today that it launched a first-in-man trial of its Smart Biopsy device, touting that the first patients in the trial have already been treated.
The first-in-man cases were performed by Dr. Noemi Weissenberg of Kfar Saba, Israel’s Meir Medical Center, the Alpharetta, Ga.-based company said.
Dune Medical’s Smart Biopsy system is a percutaneous soft tissue biopsy device that uses miniaturized sensors in the core needle to generate electrical parameters on sampled tissue in real-time. Those electrical signals are compared to histopahtologic findings to improve diagnosis and read-out.
“The in-man phase is the continuation of a broader and more comprehensive clinical trial aimed at definitive tissue characterization in the breast, Dunes first application. The collective works will be published later this year as a revolutionary solution for enhancing accuracy in biopsy diagnosis and guide future development of RF Spectroscopy across the oncology spectrum. We’re thrilled to have met this important milestone in our strategy to offer multi-cancer applications,” CEO Lori Chmura said in a press release.
Last July, Dune Medical launched a reposable version of its MarginProbe radiofrequency spectropscopy device, which can help surgeons identify remaining cancer cells in real time during a lumpectomy.
